Fate Therapeutics (FATE) Stock Price, Quote & News

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 875 1800

Website: www.fatetherapeutics.com

Address:

12278 Scripps Summit Drive, San Diego, United States

Portfoliovalue1 Dec. 24 at 7:25 PM

$FATE Merry Christmas and Happy New Year! FATE lovers! Allogenic therapy is entering a new age starting from 2026! Wish your guys would make a lot of money on this stock!

0 · Reply

Stocksprofessional Dec. 24 at 6:12 PM

$FATE Just wanted to stop by, say hello, and wish you a very Merry Christmas. Hope the holiday brings you joy, peace, and some well-deserved rest with the people you care about. 🎄

0 · Reply

Rocketman808 Dec. 24 at 3:10 PM

$FATE

0 · Reply

Rocketman808 Dec. 23 at 8:51 PM

$FATE slapped the s out of that on the way back up. wow! got 6k more shares.heavy volume day held 95

0 · Reply

SuperGreenToday Dec. 23 at 7:20 PM

$FATE Share Price: $0.97 Contract Selected: May 15, 2026 $0.5 Calls Buy Zone: $0.21 – $0.26 Target Zone: $0.35 – $0.42 Potential Upside: 53% ROI Time to Expiration: 142 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

aw20 Dec. 23 at 6:26 PM

$FATE grabbed some at 0.955 👀

0 · Reply

Rocketman808 Dec. 23 at 5:42 PM

$FATE someones offsetting tech gains. 95 cent support has been strong lets see..

0 · Reply

Rocketman808 Dec. 23 at 4:48 PM

$FATE cannot purchase calls, says not enough available due to low value of underlying asset. might just be a fidelity thing but this is a steal

0 · Reply

cta7978 Dec. 23 at 4:45 PM

$FATE Are they just shorting to screw over tax-loss sellers by 12/31? No catalysts until next year so I guess why not..

1 · Reply

murphylaw Dec. 23 at 4:26 PM

$FATE quiet 2025. Eventful 2026 probably. Hopefully it'll get to 5 dollars in 2026. Have a good feeling.

0 · Reply

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 6 weeks ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 4, 2025, 4:01 PM EST - 7 weeks ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Oct 26, 2025, 11:30 AM EDT - 2 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jun 11, 2025, 9:00 AM EDT - 7 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

May 30, 2025, 4:30 PM EDT - 7 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 28, 2025, 5:54 PM EDT - 7 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 13, 2025, 4:01 PM EDT - 8 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 8, 2025, 6:22 PM EDT - 8 months ago

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

Apr 29, 2025, 9:25 AM EDT - 8 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Mar 5, 2025, 4:01 PM EST - 10 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 4, 2025, 4:01 PM EST - 10 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Feb 14, 2025, 4:01 PM EST - 11 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 4, 2025, 7:41 PM EST - 11 months ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 20, 2024, 4:34 PM EST - 1 year ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

May 29, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Mar 19, 2024, 8:44 AM EDT - 1 year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 1, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 8:25 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2023, 12:10 PM EST - 2 years ago

Fate Therapeutics: Getting There, But Perpetually

Nov 8, 2023, 9:12 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Portfoliovalue1 Dec. 24 at 7:25 PM

$FATE Merry Christmas and Happy New Year! FATE lovers! Allogenic therapy is entering a new age starting from 2026! Wish your guys would make a lot of money on this stock!

0 · Reply

Stocksprofessional Dec. 24 at 6:12 PM

$FATE Just wanted to stop by, say hello, and wish you a very Merry Christmas. Hope the holiday brings you joy, peace, and some well-deserved rest with the people you care about. 🎄

0 · Reply

Rocketman808 Dec. 24 at 3:10 PM

$FATE

0 · Reply

Rocketman808 Dec. 23 at 8:51 PM

$FATE slapped the s out of that on the way back up. wow! got 6k more shares.heavy volume day held 95

0 · Reply

SuperGreenToday Dec. 23 at 7:20 PM

0 · Reply

aw20 Dec. 23 at 6:26 PM

$FATE grabbed some at 0.955 👀

0 · Reply

Rocketman808 Dec. 23 at 5:42 PM

$FATE someones offsetting tech gains. 95 cent support has been strong lets see..

0 · Reply

Rocketman808 Dec. 23 at 4:48 PM

$FATE cannot purchase calls, says not enough available due to low value of underlying asset. might just be a fidelity thing but this is a steal

0 · Reply

cta7978 Dec. 23 at 4:45 PM

$FATE Are they just shorting to screw over tax-loss sellers by 12/31? No catalysts until next year so I guess why not..

1 · Reply

murphylaw Dec. 23 at 4:26 PM

$FATE quiet 2025. Eventful 2026 probably. Hopefully it'll get to 5 dollars in 2026. Have a good feeling.

0 · Reply

Rocketman808 Dec. 23 at 3:46 PM

$FATE what did the fda say this time? whole allo sector hit

0 · Reply

StockDaddy68 Dec. 23 at 3:31 PM

$FATE What the HECK?!?!?

0 · Reply

Jake140 Dec. 23 at 12:27 PM

$FATE Holding...hoping that eventually...you know!

1 · Reply

cta7978 Dec. 22 at 7:54 PM

$FATE Zzzzz.. Hoping for JPM catalyst

0 · Reply

Jake140 Dec. 22 at 11:11 AM

$FATE

0 · Reply

BullDonald Dec. 21 at 11:44 PM

$FATE The Fate of the FATE is in the hand of the TUTEs. 90%~ owned by tutes !!! They mostly hold Long, But when ever they want cash, Retail traders will be their TOYs. Squide Game Vibe.

2 · Reply

cta7978 Dec. 19 at 7:40 PM

$FATE

0 · Reply

cta7978 Dec. 19 at 5:10 PM

$FATE Damn, IPSC just keeps creeping up on the T1D indication

0 · Reply

Rocketman808 Dec. 19 at 4:49 PM

$FATE weve got some call bidders on the august calls. i really dont think its getting much lower than this before the inevitable rise pre data release next year

0 · Reply

Nik7777 Dec. 19 at 2:57 PM

$FATE 🚀

0 · Reply

Jake140 Dec. 19 at 12:47 PM

$FATE

0 · Reply

murphylaw Dec. 18 at 9:28 PM

$FATE 2026 hopefully by end of January it'll get to $2.

0 · Reply

Market Cap	112.68M
Revenue (ttm)	13.63M
Net Income (ttm)	-186.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,366.54%
Debt to Equity Ratio	0.00

Volume	791,500
Avg Vol	1,687,786
Day's Range	N/A - N/A
Shares Out	115.35M
Stochastic %K	25%
Beta	2.34
Analysts	Sell
Price Target	$4.94